Treatment of Uremic Pruritus With PA101B

Completed · Phase 2 · Has a placebo group

Conditions studied: Uremic Pruritus

In brief

This is a randomized, double blind, placebo-controlled, parallel-arm, multi-center, Phase 2, proof-of-concept efficacy and safety study in patients with end-stage renal disease requiring hemodialysis. The purpose of the study is to determine the efficacy and safety profile of PA101B delivered via eFlow high efficiency nebulizer in patients with uremic pruritus who are symptomatic despite using standard treatments.

Key facts

Study ID

NCT02696499

Run by

Patara Pharma

People needed

70

Starts

2016-02-01

Expected to finish

2016-12-01

Last updated by the study team

2018-04-20

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of end-stage renal disease (ESRD) requiring hemodialysis for at least 3 months prior to the Screening Period
• Receiving conventional hemodialysis (i.e., not hemofiltration or hemodiafiltration)
• Pruritus present for at least 6 weeks of Screening
• Mean pruritus severity score on a numerical rating scale (NRS) > 4
• Patient-Assessed Disease Severity Scale Type B or C at Screening
• Documentation of a urea reduction ratio (URR) >65% or single-pooled Kt/V> 1.4 during Screening
• Willing and able to provide written informed consent

You may not qualify if…

• Current or recent history of clinically significant medical condition, laboratory abnormality, or illness that could put the patient at risk or compromise the quality of the study data as determined by the investigator
• Myocardial infarction within 6 months or unstable angina, acute coronary syndrome, or interventional coronary procedure within 2 months of Screening
• Upper or lower respiratory tract infection (including sinus infection) within 4 weeks of Screening
• Severely symptomatic cardiopulmonary disease defined by the use of home oxygen treatment, dyspnea at rest or with minimal exertion, uncontrolled arrhythmias (e.g. atrial fibrillation with inadequate rate control), or history of life-threatening arrhythmias (e.g. cardiac arrest or syncope related to arrhythmia)
• Acute exacerbation of asthma or chronic obstructive pulmonary disease resulting in hospitalization or visit to an emergency department or urgent care clinic within 6 months of Screening
• Hospitalization for any medical reason other than for a pre-planned procedure or dialysis access related procedure within the 2 weeks of Screening
• Malignancy requiring active treatment with a systemic drug
• Participation in any other investigation drug study within 4 weeks of Screening
• Current or anticipated use of baclofen, gabapentin, pregabalin and nalbuphine for the treatment of pruritus
• Current or anticipated use of glucocorticoids administered intravenously, orally, or transdermally
• Pregnant or breastfeeding females, or if of child-bearing potential unwilling to practice acceptable means of birth control or abstinence during the study

Where it is running

• Arizona Kidney Disease and Hypertension Center — Phoenix, Arizona, United States
• US Renal Care — Pine Bluff, Arkansas, United States
• Valley Renal Medical Group — Northridge, California, United States
• North America Research Institute — San Dimas, California, United States
• Pines Clinical Research, Inc. — Pembroke Pines, Florida, United States
• Genesis Clinical Research — Tampa, Florida, United States
• Boise Kidney and Hypertension Institute — Meridian, Idaho, United States
• Fresenius Medical Care of Evergreen Park — Evergreen Park, Illinois, United States
• Renal Medicine Associates — Albuquerque, New Mexico, United States
• US Renal Care — Gallup, New Mexico, United States
• Ridgewood Dialysis Center — Ridgewood, New York, United States
• Brookview Hills Research Associates LLC — Winston-Salem, North Carolina, United States
• Southeast Renal Research Institute — Chattanooga, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.